Division of Cardiac & Vascular Sciences, St George's University of London, London, UK.
J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):36S-50S. doi: 10.1177/1074248410371947. Epub 2010 Oct 12.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a significant health care issue. The diagnosis and management of AF uses a significant proportion of the health care budget and is responsible for substantial morbidity and mortality. Restoration and maintenance of sinus rhythm is still an important treatment option for symptomatic AF. Anti-arrhythmic drugs (AADs) have had inconsistent results for the prevention of recurrent AF and have been hampered by significant adverse effects. Catheter ablation has rapidly evolved and is fast becoming an alternative for AF prevention. Although multiple treatment options exist, no single modality is effective for all patients. This review outlines best current practice for AF prevention and future perspectives, focusing on new and promising developments in antiarrhythmic drug therapy, strategies for ablation therapy, and forms of hybrid therapy that may offer improved outcomes in selected patients.
心房颤动（AF）是最常见的持续性心律失常，也是一个重大的医疗保健问题。AF 的诊断和管理使用了相当大比例的医疗保健预算，并且与相当大的发病率和死亡率有关。恢复和维持窦性心律仍然是治疗有症状 AF 的重要选择。抗心律失常药物（AADs）在预防复发性 AF 方面的效果不一致，并且受到严重不良反应的阻碍。导管消融术迅速发展，正在迅速成为预防 AF 的一种替代方法。尽管存在多种治疗选择，但没有单一的方法对所有患者都有效。本综述概述了 AF 预防的当前最佳实践和未来展望，重点介绍了抗心律失常药物治疗、消融治疗策略以及可能为选定患者提供更好结果的混合治疗形式的新的有前途的进展。
